Yunnan Baiyao Group stock (CNE100000G78): Key player in China's tartar control toothpaste market

Yunnan Baiyao Group, known for its traditional Chinese medicine heritage, holds a leading role among domestic brands in China's tartar control toothpaste market. This sub-segment is projected to reach ¥6–8 billion in retail value in 2026, representing 9–11% of total toothpaste sales, up from 7% in 2020, driven by an aging population where adults over 45 are expected to comprise 38% by 2030, according to IndexBox 2026 report. The company's flagship Yunnan Baiyao products, rooted in proprietary herbal blends like Radix Notoginseng, continue to support its market presence.

As of: 05/12/2026

By the editorial team – specialized in equity coverage.

Yunnan Baiyao Group: core business model

Yunnan Baiyao Group specializes in traditional Chinese medicines, with its namesake product Yunnan Baiyao renowned for supporting blood clotting homeostasis. The proprietary blend includes key ingredients like 200mg Radix Notoginseng and 85mg Ajuga Forrestii Diels per 0.5g serving, as detailed on product labels from authorized distributors. Beyond core pharmaceuticals, the group has diversified into consumer health products, including toothpaste leveraging its herbal expertise.

Listed on the Shenzhen Stock Exchange under ticker 000538.SZ, the company operates primarily in China but garners interest from US investors tracking exposure to Asia's healthcare and FMCG sectors. Its business model combines R&D in traditional formulas with modern manufacturing, serving both prescription and over-the-counter markets.

Main revenue and product drivers for Yunnan Baiyao Group

The tartar control toothpaste category, where Yunnan Baiyao leads domestic brands alongside Darlie, contributes to the broader ¥70 billion Chinese oral-care market. This segment's growth is fueled by higher calculus formation in older demographics, positioning the company's toothpaste line as a key revenue driver. Traditional medicines remain the cornerstone, with Yunnan Baiyao capsules and powders driving the majority of sales.

US investors may note the company's role in China's consumer staples, offering indirect exposure to demographic shifts like population aging, which boosts demand for preventive oral care products.

Industry trends and competitive position

China's oral-care market favors domestic players holding 55–65% retail value share, with Yunnan Baiyao benefiting from brand loyalty in tartar control. Global giants like Colgate influence the space via partnerships, but local herbal formulations provide a competitive edge. The sector's expansion aligns with rising health awareness post-pandemic.

Conclusion

Yunnan Baiyao Group continues to leverage its traditional medicine legacy in growing consumer segments like tartar control toothpaste, amid favorable demographics in China. While market projections highlight opportunities, investors should monitor competitive dynamics and economic factors influencing FMCG spending. The stock remains a notable name for those eyeing China healthcare exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.